Sugi Predict

Sugi Predict / Compounds / Adegrapepimut-S

Adegrapepimut-S

Adegrapepimut-S

SCHEMBL29502686

CC(C)C[C@H](NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CCCN1C(=O)[C@H](C)NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)NC(=O)[C@@H](N)Cc1c[nH]c2ccccc12)C(C)C)C(=O)O

nearest known ligand 0.60

Full drug profile on Sugi Atlas →

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
▸ GLP1R P43220 13/20 0.60
▸ GIPR P48546 13/20 0.60
▸ CXCL8 P10145 5/20 0.59
▸ CXCR4 P61073 2/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31182517 0.86 GLP1R (0.62) GLP1RGIPRCXCL8CXCR4
SCHEMBL30168658 0.85 GLP1R (0.61) GLP1RGIPRCXCL8
SCHEMBL29706185 0.85 GLP1R (0.65) GLP1RGIPR
SCHEMBL29706160 0.85 GLP1R (0.67) GLP1RGIPR
SCHEMBL30792345 0.84 GNRHR (0.56) GLP1RGIPRCXCL8CXCR4
SCHEMBL30906407 0.83 GLP1R (0.58) GLP1RGIPR
SCHEMBL30647310 0.83 GLP1R (0.65) GLP1RGIPR
SCHEMBL30647309 0.83 GLP1R (0.66) GLP1RGIPR
SCHEMBL30647305 0.83 GLP1R (0.65) GLP1RGIPR
SCHEMBL31664364 0.83 NPY1R (0.67) GLP1RGIPRCXCR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3199175-B1 PHARMACEUTICAL COMPOSITION FOR INJECTION SUMITOMO DAINIPPON PHARMA CO LTD (JP) 2022-03-23 — — EP claimed
US-20230089426-A1 METHODS FOR THE TREATMENT OF CANCER JOUNCE THERAPEUTICS, INC. 2023-03-23 — — US disclosed
US-20220332823-A1 METHODS OF TREATING CANCER JOUNCE THERAPEUTICS, INC. 2022-10-20 — — US disclosed
US-20220289847-A1 METHODS FOR THE TREATMENT OF CANCER JOUNCE THERAPEUTICS, INC. 2022-09-15 — — US disclosed
US-11292840-B2 Methods of treating cancer in a subject having elevated ICOS and/or T-bet levels of CD+4 cells by administering an ICOS agonist JOUNCE THERAPEUTICS, INC. (US) 2022-04-05 — — US disclosed
EP-3199175-B1 PHARMACEUTICAL COMPOSITION FOR INJECTION SUMITOMO DAINIPPON PHARMA CO LTD (JP) 2022-03-23 — — EP disclosed
Send feedback